August 2012
-
The Respiratory Technology Team of the Woolcock Institute for Medical Research (WIMR) has announced that a $12,000 International Research Collaboration Award from the University of Sydney will fund a collaboration between the team and Carsten… Read more . . .
-
Rigel Pharmaceuticals’ R343 inhaled SYK inhibitor has failed to meet primary or secondary endpoints in a Phase 2 study, the company said. As a result, Rigel will discontinue development of the product for the treatment… Read more . . .
-
Since 1968, ABC Laboratories has delivered expert scientific support to companies working to improve human and animal health. As a member of the ABC team, you’ll work alongside respected technical experts dedicated to scientific excellence… Read more . . .
-
Since 1968, ABC Laboratories has delivered expert scientific support to companies working to improve human and animal health. As a member of the ABC team, you’ll work alongside respected technical experts dedicated to scientific excellence… Read more . . .
-
Lightlake Therapeutics has announced that the US National Institute on Drug Abuse (NIDA) wiill sponsor a Phase 1 pharmacokinetic study of Lightlake’s intranasal naloxone. If the results of the study are positive, the company said,… Read more . . .
-
Forest Laboratories and Almirall have announced that a planned 4th quarter 2013 NDA submission for their aclidinium bromide/formoterol dry powder inhaler will be delayed due to the need to address FDA concerns regarding chemistry, manufacturing… Read more . . .
-
MannKind Corporation has announced that preliminary results from two Phase 3 clinical studies of Afrezza inhaled insulin met their primary endpoints. In a study in patients with Type 1 diabetes comparing Afrezza to insulin aspart,… Read more . . .
-
Aegis Therapeutics has announced that it has received New Zealand Patent No. 5937828 for fast acting formulations of triptans that can be administered as nasal, buccal, or sublingual sprays. The company’s Intravail formulations have been… Read more . . .
-
According to Dance Biopharm, a 12-patient, randomized, semi-blinded Phase 1/2 pharmacokinetic study of its Adagio inhaled insulin in patients with Type 1 diabetes demonstrated the safety of the product and showed that it did not… Read more . . .
-
Adamis Pharmaceuticals has announced that it will exclusively license and then acquire 3M’s Taper API-only dry powder inhaler. The company said that “Upon completion of development and clinical activities required to obtain required regulatory approval,… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland